We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
-26.85%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$235M
AUM Growth
-$66.1M
Cap. Flow
+$31.7M
Cap. Flow %
13.5%
Top 10 Hldgs %
83.33%
Holding
22
New
2
Increased
11
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
TSVT
2seventy bio
TSVT
+$13.9M
2
RPTX
Repare Therapeutics
RPTX
+$5.47M
3
CGEM icon
Cullinan Oncology
CGEM
+$3.73M
4
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
+$3.69M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$2.45M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$6.61M
2
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$1.12M
3
CMPX icon
Compass Therapeutics
CMPX
+$401K

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Miscellaneous 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$59.9M 25.45%
1,585,096
-167,147
-10% -$6.61M
RPTX
2
DELISTED
Repare Therapeutics
RPTX
$36.8M 15.63%
2,581,097
+368,841
+17% +$5.47M
CGEM icon
3
Cullinan Oncology
CGEM
$1.45B
$28.8M 12.26%
2,753,047
+276,327
+11% +$3.73M
PLRX icon
4
Pliant Therapeutics
PLRX
$71.2M
$18.6M 7.92%
2,657,457
+87,978
+3% +$898K
VECT
5
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$14.5M 6.18%
3,084,310
+408,902
+15% +$2.14M
TSVT
6
DELISTED
2seventy bio
TSVT
$14M 5.95%
+819,672
New +$13.9M
OMGA
7
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$6.59M 2.8%
1,055,882
– –
LRMR icon
8
Larimar Therapeutics
LRMR
$421M
$6.14M 2.61%
1,515,148
– –
FRLN
9
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$5.45M 2.32%
324,155
+199,062
+159% +$3.69M
KZR
10
DELISTED
Kezar Life Sciences
KZR
$5.23M 2.22%
31,461
+4,236
+16% +$608K
IMA
11
ImageneBio Inc
IMA
$60.5M
$4.97M 2.11%
67,896
– –
ONCR
12
DELISTED
Oncorus, Inc.
ONCR
$4.3M 1.83%
2,417,436
+310,533
+15% +$870K
AKUS
13
DELISTED
Akouos Inc
AKUS
$3.97M 1.69%
836,120
– –
CMPX icon
14
Compass Therapeutics
CMPX
$454M
$3.88M 1.65%
2,829,712
-193,980
-6% -$401K
ORTX
15
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.78M 1.61%
530,775
-114,211
-18% -$1.12M
GTHX
16
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.71M 1.58%
488,635
+258,635
+112% +$2.45M
INZY
17
DELISTED
Inozyme Pharma
INZY
$3.65M 1.55%
892,057
– –
KROS icon
18
Keros Therapeutics
KROS
$223M
$3.38M 1.44%
62,229
+44,711
+255% +$2.3M
CRVS icon
19
Corvus Pharmaceuticals
CRVS
$1.24B
$2.79M 1.19%
1,703,137
+1,303,137
+326% +$2.39M
OVID icon
20
Ovid Therapeutics
OVID
$572M
$2.68M 1.14%
852,888
+452,888
+113% +$1.42M
DTIL icon
21
Precision BioSciences
DTIL
$232M
$1.87M 0.79%
20,221
– –
XBI icon
22
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$206K 0.09%
+222,500
New +$20.5M

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, CHI Advisors held 22 positions worth $235M, down 22% from $301M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

CHI Advisors deployed $31.7M of net new capital in Q1 2022, opening 2 new positions and adding to 11 existing holdings. Its largest new stake was 2seventy bio: 819,672 shares worth $14M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Prometheus Biosciences, Inc. Common Stock, an estimated $6.61M trimmed.

  • CHI Advisors's largest Q1 2022 buy was 2seventy bio: 819,672 shares worth $14M.
  • CHI Advisors added most to Repare Therapeutics in Q1 2022, an estimated $5.47M increase.
  • CHI Advisors's biggest Q1 2022 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $6.61M.
  • CHI Advisors's ten largest holdings make up 83% of its $235M portfolio in Q1 2022.
  • CHI Advisors opened 2 new positions and closed 0 in Q1 2022.
  • CHI Advisors's portfolio value fell 22% quarter-over-quarter to $235M.

Based on CHI Advisors's 13F filing for Q1 2022, filed 16 May 2022.